Literature DB >> 7977641

Gene expression of transforming growth factor-beta 1 and its type II receptor in giant cell tumors of bone. Possible involvement in osteoclast-like cell migration.

M H Zheng1, Y Fan, S J Wysocki, A T Lau, T Robertson, M Beilharz, D J Wood, J M Papadimitriou.   

Abstract

Giant cell tumor of bone (GCT) is a relatively rare skeletal neoplasm characterized by multinuclear giant cells (osteoclast-like cells) scattered in a mass of mononuclear cells. The currently favored hypothesis for the origin of cells within GCT is that the multinuclear giant cells are reactive osteoclasts, whereas the truly neoplastic cells are the major component of the mononuclear population. However, the pathological significance and the precise relationship of tumor cells and osteoclast-like cells in GCT have not been fully established. In this study, we evaluated two GCTs for the presence of transforming growth factor-beta 1 (TGF-beta 1) and TGF-beta type II receptor gene transcripts and attempted to establish a possible role for TGF-beta 1 in the interaction between tumor cells and osteoclast-like cells. By using in situ hybridization and Northern blot analysis, we have demonstrated that TGF-beta 1 mRNA transcript is consistently detected in both tumor mononuclear cells and osteoclast-like cells, whereas TGF-beta type II receptor gene transcript is only present in osteoclast-like cells. Moreover, isolated rat osteoclasts were tested for their ability to migrate in response to GCT-conditioned medium (GCTCM) in an in vitro chemotactic assay. Our results showed that GCTCM stimulates the migration of osteoclasts in a dose-dependent manner. Interestingly, only osteoclasts containing less than three nuclei can migrate through 12-mu pore filters. Addition of monoclonal antibody against TGF-beta significantly reduced but did not abolish the chemotactic activity of GCTCM. Moreover, TGF-beta type II receptor mRNA has been demonstrated in the normal rat osteoclasts and may be involved in the chemotactic action of TGF-beta 1. We concluded that TGF-beta 1, possibly in concert with other cytokines, is involved in the recruitment of osteoclast-like cells in GCT by acting in an autocrine or paracrine fashion.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7977641      PMCID: PMC1887430     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  39 in total

1.  Giant-cell tumor: a study of 195 cases.

Authors:  D C Dahlin; R E Cupps; E W Johnson
Journal:  Cancer       Date:  1970-05       Impact factor: 6.860

2.  Identification of human osteoclasts with monoclonal antibodies.

Authors:  M A Horton; J A Pringle; T J Chambers
Journal:  N Engl J Med       Date:  1985-04-04       Impact factor: 91.245

3.  An immunohistological study of giant-cell tumour of bone: evidence for an osteoclast origin of the giant cells.

Authors:  N A Athanasou; E Bliss; K C Gatter; A Heryet; C G Woods; J O McGee
Journal:  J Pathol       Date:  1985-11       Impact factor: 7.996

4.  The effects of calcium regulating hormones on bone resorption by isolated human osteoclastoma cells.

Authors:  T J Chambers; K Fuller; P M McSheehy; J A Pringle
Journal:  J Pathol       Date:  1985-04       Impact factor: 7.996

5.  A histological and immunoenzymatic study on the histogenesis of "giant cell tumor of bones".

Authors:  V Bouropoulou; G Kontogeorgos; Z Manika
Journal:  Pathol Res Pract       Date:  1985-07       Impact factor: 3.250

6.  Biologic characterization of human bone tumors. III. Giant cell tumor of bone. A combined electron microscopical, histochemical, and autoradiographical study.

Authors:  A Roessner; D B von Bassewitz; W Schlake; G Thorwesten; E Grundmann
Journal:  Pathol Res Pract       Date:  1984-05       Impact factor: 3.250

7.  Delineation of four cell types comprising the giant cell tumor of bone. Expression of Ia and monocyte-macrophage lineage antigens.

Authors:  G R Burmester; R J Winchester; A Dimitriu-Bona; M Klein; G Steiner; H A Sissons
Journal:  J Clin Invest       Date:  1983-06       Impact factor: 14.808

8.  Monocyte-macrophage lineage of giant cell tumor of bone. Establishment of a multinucleated cell line.

Authors:  T S Huang; A D Green; C W Beattie; T K Das Gupta
Journal:  Cancer       Date:  1993-03-01       Impact factor: 6.860

9.  Giant cell tumor bone. Enzyme histochemical, biochemical and tissue culture studies.

Authors:  H Yoshida; M Akeho; T Yumoto
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1982

10.  Cell surface characterization of the human osteoclast: phenotypic relationship to other bone marrow-derived cell types.

Authors:  M A Horton; E F Rimmer; D Lewis; J A Pringle; K Fuller; T J Chambers
Journal:  J Pathol       Date:  1984-12       Impact factor: 7.996

View more
  16 in total

1.  Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation.

Authors:  L Huang; J Xu; D J Wood; M H Zheng
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

2.  Collagenase expression and activity in the stromal cells from giant cell tumour of bone.

Authors:  Robert W Cowan; Isabella W Y Mak; Nigel Colterjohn; Gurmit Singh; Michelle Ghert
Journal:  Bone       Date:  2009-02-12       Impact factor: 4.398

Review 3.  An overview of the role of cancer stem cells in spine tumors with a special focus on chordoma.

Authors:  Mojdeh Safari; Alireza Khoshnevisan
Journal:  World J Stem Cells       Date:  2014-01-26       Impact factor: 5.326

Review 4.  Role of NADPH oxidase in formation and function of multinucleated giant cells.

Authors:  Mark T Quinn; Igor A Schepetkin
Journal:  J Innate Immun       Date:  2009-07-07       Impact factor: 7.349

5.  Role of the VEGF-Flt-1-FAK pathway in the pathogenesis of osteoclastic bone destruction of giant cell tumors of bone.

Authors:  Yoshihiro Matsumoto; Yuko Okada; Jun-Ichi Fukushi; Satoshi Kamura; Toshifumi Fujiwara; Keiichiro Iida; Mihoko Koga; Shuichi Matsuda; Katsumi Harimaya; Akio Sakamoto; Yukihide Iwamoto
Journal:  J Orthop Surg Res       Date:  2010-11-09       Impact factor: 2.359

Review 6.  RANKL/RANK/OPG: key therapeutic target in bone oncology.

Authors:  Kosei Ando; Kanji Mori; Francoise Rédini; Dominique Heymann
Journal:  Curr Drug Discov Technol       Date:  2008-09

7.  Transforming growth factor-beta1 (TGF-beta1) induces human osteoclast apoptosis by up-regulating Bim.

Authors:  Nicolas Houde; Estelle Chamoux; Martine Bisson; Sophie Roux
Journal:  J Biol Chem       Date:  2009-07-01       Impact factor: 5.157

8.  Roles of stromal cell RANKL, OPG, and M-CSF expression in biphasic TGF-beta regulation of osteoclast differentiation.

Authors:  Mary Karst; Genevieve Gorny; Rachelle J Sells Galvin; Merry Jo Oursler
Journal:  J Cell Physiol       Date:  2004-07       Impact factor: 6.384

9.  TGF-β induces Wnt10b in osteoclasts from female mice to enhance coupling to osteoblasts.

Authors:  Kuniaki Ota; Patrick Quint; Ming Ruan; Larry Pederson; Jennifer J Westendorf; Sundeep Khosla; Merry Jo Oursler
Journal:  Endocrinology       Date:  2013-07-16       Impact factor: 4.736

10.  Matrix metalloproteinase 9 (gelatinase B) is expressed in multinucleated giant cells of human giant cell tumor of bone and is associated with vascular invasion.

Authors:  Y Ueda; K Imai; H Tsuchiya; N Fujimoto; I Nakanishi; S Katsuda; M Seiki; Y Okada
Journal:  Am J Pathol       Date:  1996-02       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.